非小细胞肺癌EGFR-TKI耐药与p53基因突变的研究进展

doi:10.11958/20252986

天津医药 ›› 2026, Vol. 54 ›› Issue (3): 333-336.doi: 10.11958/20252986

• 综述 • 上一篇

非小细胞肺癌EGFR-TKI耐药与p53基因突变的研究进展

黄熷远(), 付靖, 赵亚, 王龙灏, 仓顺东^△()

郑州大学人民医院，河南省人民医院肿瘤中心（邮编450000）

收稿日期:2025-09-22 修回日期:2025-12-05 出版日期:2026-03-15 发布日期:2026-03-17
通讯作者: △E-mail：cangshundong@163.com
作者简介:黄熷远（1999），男，硕士在读，主要从事肺部肿瘤方面研究。E-mail：hzyhyfx@163.com
基金资助:
河南省重点研发专项(231111311900)

Research progress on the relationship between EGFR-TKI resistance and p53 mutation in non-small cell lung cancer

HUANG Zengyuan(), FU Jing, ZHAO Ya, WANG Longhao, CANG Shundong^△()

Department of Cancer Center, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou 450000 China

Received:2025-09-22 Revised:2025-12-05 Published:2026-03-15 Online:2026-03-17
Contact: △E-mail：cangshundong@163.com

黄熷远, 付靖, 赵亚, 王龙灏, 仓顺东. 非小细胞肺癌EGFR-TKI耐药与p53基因突变的研究进展[J]. 天津医药, 2026, 54(3): 333-336.

HUANG Zengyuan, FU Jing, ZHAO Ya, WANG Longhao, CANG Shundong. Research progress on the relationship between EGFR-TKI resistance and p53 mutation in non-small cell lung cancer[J]. Tianjin Medical Journal, 2026, 54(3): 333-336.

摘要/Abstract

摘要：

表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗非小细胞肺癌（NSCLC）失败的最主要原因是靶向药物耐药，而产生耐药性的最主要原因是抑癌基因p53突变。如何阻止或逆转p53突变从而解决晚期NSCLC对EGFR-TKI耐药已经成为该领域的研究热点。该文总结了p53的常见突变类型及其影响EGFR-TKI耐药的相关机制，以及如何干预p53突变从而逆转EGFR-TKI耐药，对NSCLC患者EGFR-TKI耐药与p53突变的关系进行了深入探讨。

关键词: 癌, 非小细胞肺, 基因, p53, 突变, 表皮生长因子受体酪氨酸激酶抑制剂

Abstract:

The main reason for the failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of non-small cell lung cancer (NSCLC) is targeting drug resistance, and the main cause of drug resistance is the mutation of the tumor suppressor gene p53. How to prevent or reverse p53 mutations to solve the problem of EGFR-TKI resistance in advanced NSCLC has become a research hotspot in this field. This article summarizes the common mutation types of p53 and their related mechanisms affecting EGFR-TKI resistance, as well as how to intervene in p53 mutations to reverse EGFR-TKI resistance, and conducts an in-depth discussion on the relationship between EGFR-TKI resistance and p53 mutations in NSCLC patients.

Key words: carcinoma, non-small-cell lung, genes, p53, mutation, EGFR-TKI

中图分类号:

R734.2

参考文献 34

[1]	ABUKHALIL A D, MANSOUR K, ALHAJ W, et al. Non-small cell lung cancer (NSCLC): characteristics,risk factors,molecular profile patterns,and treatment - a retrospective cohort study from Palestine[J]. J Egypt Natl Canc Inst, 2025, 37(1):40. doi:10.1186/s43046-025-00298-8.
[2]	SPINI A, GINI R, ROSELLINI P, et al. First-line pharmacotherapies and survival among patients diagnosed with non-resectable NSCLC:a real-life setting study with gender prospective[j]. cancers (basel), 2021, 13(23) doi:10.3390/cancers13236129.
[3]	ZHANG J, VOKES N, LI M, et al. Overcoming EGFR-TKI resistance by targeting the tumor microenvironment[J]. Chin Med J Pulm Crit Care Med, 2024, 2(3):151-161. doi:10.1016/j.pccm.2024.08.002.
[4]	CASWELL D R, GUI P, MAYEKAR M K, et al. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance[J]. Nat Genet, 2024, 56(1):60-73. doi:10.1038/s41588-023-01592-8.
[5]	HAN B, FEINSTEIN T, SHI Y, et al. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen(DUBLIN-3):a phase 3,international,multicentre,single-blind,parallel group,randomised controlled trial[J]. Lancet Respir Med, 2024, 12(10):775-786. doi:10.1016/S2213-2600(24)00178-4.
[6]	VOKES N I, CHAMBERS E, NGUYEN T, et al. Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma[J]. J Thorac Oncol, 2022, 17(6):779-792. doi:10.1016/j.jtho.2022.02.011.
[7]	IBUSUKI R, IWAMA E, SHIMAUCHI A, et al. TP53 gain-of-function mutations promote osimertinib resistance via TNF-α-NF-κB signaling in EGFR-mutated lung cancer[J]. NPJ Precis Oncol, 2024, 8(1):60. doi:10.1038/s41698-024-00557-2.
[8]	CHEN X, XIE L, QIAO K, et al. The pan-cancer analysis identified DIAPH3 as a diagnostic biomarker of clinical cancer[J]. Aging (Albany NY), 2023, 15(3):689-704. doi:10.18632/aging.204459.
[9]	MONDAL P, ROY K S, BHAGAT S V, et al. Disrupting the interaction between a p53 gain-of-function mutant and the transcriptional co-activator PC4 reverses drug resistance in cancer cells[J]. FEBS Lett, 2024, 598(12):1532-1542. doi:10.1002/1873-3468.14890.
[10]	CHEN X, ZHANG T, SU W, et al. Mutant p53 in cancer:from molecular mechanism to therapeutic modulation[J]. Cell Death Dis, 2022, 13(11):974. doi:10.1038/s41419-022-05408-1.
[11]	ALSULAMI A F. Mutational disruption of TP53:a structural approach to understanding chemoresistance[J]. Int J Mol Sci, 2025, 26(18):9135. doi:10.3390/ijms26189135.
[12]	BRAND T M, DUNN E F, IIDA M, et al. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab[J]. Cancer Biol Ther, 2011, 12(5):436-446. doi:10.4161/cbt.12.5.16394.
[13]	ZHAO Y, ZHOU K, XIA X, et al. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells[J]. Cell Cycle. 2023, 22(2):200-212. doi:10.1080/15384101.2022.2111769.
[14]	LIU H, JIA X, LUO K, et al. TCRP1 activated by mutant p53 promotes NSCLC proliferation via inhibiting FOXO3a[J]. Oncogenesis, 2022, 11(1):19. doi:10.1038/s41389-022-00392-9.
[15]	ZHANG Y, LI S, LYU Z, et al. The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients[J]. J Thorac Dis, 2022, 14(1):185-193. doi:10.21037/jtd-21-1921.
[16]	WANG X, QIN Z, QIU W, et al. Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer[J]. Eur J Med Chem, 2024, 277:116711. doi:10.1016/j.ejmech.2024.116711.
[17]	CHEN Z, VALLEGA K A, CHEN H, et al. The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition[J]. Pharmacol Res, 2022, 175:105998. doi:10.1016/j.phrs.2021.105998.
[18]	DEMPEK WCM, FENCHEL K. Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-review[J]. Transl Cancer Res, 2024, 13(11):6540-6549. doi:10.21037/tcr-24-690.
[19]	HAO L, CHEN H, WANG L, et al. Transformation or tumor heterogeneity:Mutations in EGFR,SOX2,TP53,and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer[J]. Thorac Cancer, 2023, 14(11):1036-1041. doi:10.1111/1759-7714.14832.
[20]	CHOI Y R, KANG E H, KIM S, et al. Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer[J]. Br J Cancer, 2023, 128(12):2186-2196. doi:10.1038/s41416-023-02264-4.
[21]	BELLI S, ESPOSITO D, ASCIONE C M, et al. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer[J]. Cancer Lett, 2024, 593:216968. doi:10.1016/j.canlet.2024.216968.
[22]	卢敏, 李鑫, 林鹏真, 等. 肿瘤蛋白p53诱导的糖酵解调节磷酸酶在恶性肿瘤中作用机制的研究进展[J]. 癌症进展, 2024, 22(19):2096-2100,2126.
	LU M, LI X, LIN P Z, et al. Research progress on the mechanism of Tumor Protein p53-induced glycolysis regulating phosphatase in malignant tumors[J]. Oncology Progress, 2024, 22(19):2096-2100,2126.
[23]	SHEN C, CHAN R, LIN B, et al. Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation[J]. Theranostics, 2023, 13(13):4650-4666. doi:10.7150/thno.85855.
[24]	DESOUSAPINTO M, FONTOURA LGO, DAROSABORGES I, et al. Evaluation of infliximab-induced genotoxicity and possible action on BCL-2 and P53 genes[J]. J Toxicol Environ Health A, 2024, 87(18):752-761. doi:10.1080/15287394.2024.2368619.
[25]	DETILLEUX D, RAYNAUD P, PRADET-BALADE B, et al. The TRRAP transcription cofactor represses interferon-stimulated genes in colorectal cancer cells[J]. Elife, 2022, 11:e69705. doi:10.7554/eLife.69705.
[26]	HUANG Y, CHE X, WANG P W, et al. p53/MDM2 signaling pathway in aging,senescence and tumorigenesis[J]. Semin Cancer Biol, 2024, 101:44-57. doi:10.1016/j.semcancer.2024.05.001.
[27]	LIAO W, ZHANG R, CHEN G, et al. Berberine synergises with ferroptosis inducer sensitizing NSCLC to ferroptosis in p53-dependent SLC7A11-GPX4 pathway[J]. Biomed Pharmacother, 2024, 176:116832. doi:10.1016/j.biopha.2024.116832.
[28]	CAI B, BAI Z, LIEN C, et al. NAMPT inhibitor and P73 activator represses P53 R175H mutated HNSCC cell proliferation in a synergistic manner[J]. Biomolecules, 2022, 12(3):438. doi:10.3390/biom12030438.
[29]	WANG Y, WANG L, HUANG Y, et al. Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73[J]. Acta Pharmacol Sin, 2025, 46(6):1722-1732. doi:10.1038/s41401-025-01474-1.
[30]	XIA Y, LI X, SUN W. Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China[J]. Curr Gene Ther, 2020, 20(2):127-141. doi:10.2174/1566523220999200731003206.
[31]	QI L, LI G, LI P, et al. Twenty years of Gendicine^® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology[J]. Genes Dis, 2024, 11(4):101155. doi:10.1016/j.gendis.2023.101155.
[32]	TYUMENTSEVA M, TYUMENTSEV A, AKIMKIN V. CRISPR/Cas9 landscape:current state and future perspectives[J]. Int J Mol Sci, 2023, 24(22):16077. doi:10.3390/ijms242216077.
[33]	GUO C, MA X, GAO F, et al. Off-target effects in CRISPR/Cas9 gene editing[J]. Front Bioeng Biotechnol, 2023, 11:1143157. doi:10.3389/fbioe.2023.1143157.
[34]	BABU J Y M, MANOHARAN R. NUAKs facilitate mTOR-mediated NSCLC proliferation and metastasis by modulating glucose metabolism and inhibiting p53 activity[J]. Biochim Biophys Acta Mol Cell Res, 2025, 1872(3): 119922. doi:10.1016/j.bbamcr.2025.119922.

非小细胞肺癌EGFR-TKI耐药与p53基因突变的研究进展

Research progress on the relationship between EGFR-TKI resistance and p53 mutation in non-small cell lung cancer

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 34

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱海燕, 王烨, 尹艳. 老年NSCLC患者术后胃肠功能紊乱的危险因素研究[J]. 天津医药, 2026, 54(3): 289-294.
[2]	王丹, 金卓婷, 潘长清, 郑茜文, 于文亮, 邓艳梅, 张勇. 绵阳地区育龄女性FMR1和SMN1基因与耳聋相关基因筛查情况分析[J]. 天津医药, 2026, 54(3): 329-332.
[3]	吴蝶, 丁利军. 氨基酸代谢调控卵巢衰老研究新进展[J]. 天津医药, 2026, 54(2): 139-144.
[4]	王喆, 邱林, 马贲. 番茄来源胞外囊泡样颗粒对口腔鳞状细胞癌的作用效果研究[J]. 天津医药, 2026, 54(2): 145-150.
[5]	黄慧琦, 伍秋苑, 张昆, 李佩贤, 熊亚明, 叶国麟, 周丹. 川楝素联合奥拉帕尼在三阴性乳腺癌中的抗肿瘤机制研究[J]. 天津医药, 2025, 53(9): 897-902.
[6]	周鹏鹏, 丁烁, 姚卫康, 罗祎. 原发性肝癌患者术前免疫因素及与病理特征的关系[J]. 天津医药, 2025, 53(9): 952-956.
[7]	杨桃, 全艳, 张加孟, 谢清耘, 黄麟洲. 甲状腺结节细针穿刺细胞学联合BRAF基因检测在甲状腺良恶性肿瘤鉴别诊断中的应用价值[J]. 天津医药, 2025, 53(9): 972-975.
[8]	刘虹, 张玥玥, 王一琳, 王彩丽, 王晓敏, 毛敏, 李燕. MicroRNA-34a通过调控Wnt途径影响慢性淋巴细胞白血病进展的机制探讨[J]. 天津医药, 2025, 53(8): 785-790.
[9]	蒋苏, 李东霞, 吕新翔, 崔艳红, 吕李婷. 基于PI3K/Akt/NF-κB信号通路探讨黄连素对特应性皮炎大鼠皮肤病理变化的治疗作用[J]. 天津医药, 2025, 53(7): 679-683.
[10]	韩建存, 周谊. 川陈皮素调节FAK/AKT信号通路对喉鳞状细胞癌细胞增殖和凋亡的影响[J]. 天津医药, 2025, 53(6): 561-565.
[11]	李建林, 孙思进, 王大力. Ⅰ—Ⅱ期非小细胞肺癌胸腔镜术后心肺并发症的影响因素及预测模型构建[J]. 天津医药, 2025, 53(6): 583-588.
[12]	杜昀泽, 唐琼. 常规胸腔积液及血清学检测鉴别结核性及恶性胸腔积液的临床价值[J]. 天津医药, 2025, 53(6): 619-624.
[13]	马春梅, 于鹏, 张其程, 杨磊, 李棣华, 谭建, 孟召伟. 异硫氰酸苄酯联合索拉非尼治疗未分化甲状腺癌机制探讨[J]. 天津医药, 2025, 53(5): 449-455.
[14]	余朝霞, 马贲, 邱林, 高倩, 尼娜. 基于网络药理学和实验验证探究鲍式层孔菌多酚的抗头颈鳞癌机制[J]. 天津医药, 2025, 53(5): 456-461.
[15]	杜凌云, 王耀武, 任楠. 肾透明细胞癌中PRMT2、TRAF2与转移相关基因表达对预后的评估价值[J]. 天津医药, 2025, 53(5): 492-497.